News|Articles|November 21, 2026

COVID-19 Vaccine Choice May Matter for Older Adults, VA Data Suggest

Listen
0:00 / 0:00

Key Takeaways

  • Matched VA cohort (55,349 mRNA-1283; 239,150 BNT162b2) showed 35.9% lower medically attended COVID-19 risk with mRNA-1283 over 150 days in older, comorbid veterans.
  • Comparative effectiveness favored mRNA-1283 for severe disease, including 47% relative reduction in COVID-19 hospitalization and absolute reductions of 10 events and 2.2 hospitalizations per 10,000 vaccinated.
SHOW MORE

With COVID-19 shots now a shared decision for some, VA data give pharmacists head-to-head evidence to guide older adults’ choices.

Among more than 294,000 veterans over 65, those who got Moderna’s mRNA-1283 (mNEXSPIKE) during the 2025-2026 season had an estimated 35.9% lower risk of COVID-19 than those who received Pfizer-BioNTech’s BNT162b2 (Comirnaty), according to a VA cohort study.1

Despite shifting vaccine guidance and debates on the federal level, “it’s business as usual for every patient population, not just our immunocompromised patients,” Kelly Goode, PharmD, BCPS, FAPhA, FCCP, professor in the department of pharmacotherapy and outcomes science at the School of Pharmacy at Virginia Commonwealth University, told Drug Topics® in a previous interview. “If you’ve got somebody there ready to go who wants [influenza, COVID-19, and respiratory syncytial virus (RSV)] vaccines, and they’re indicated for all 3, by all means, let’s get them vaccinated.”

READ MORE: COVID-19 Vaccines Paid Off Up to $809 Per Dollar Spent in 2021

However, as data from a recent JAMA Network Open study reveal, simply receiving a vaccination may not be maximizing protection among patients, especially those 65 and older.

Real-World Evidence Highlights Reduced Hospitalizations and Cardiovascular Risk

The head-to-head Veterans Health Administration study evaluated LP.8.1-formulated vaccines across up to 150 days of follow-up during the 2025-2026 respiratory virus season. Analyzing a matched cohort of 55,349 mRNA-1283 recipients and 239,150 BNT162b2 recipients, researchers examined outcomes in a population characterized by an elevated chronic disease burden.1

Beyond reducing overall medically attended infections by 35.9%, receiving mRNA-1283 was associated with a 47% relative risk reduction against COVID-19 hospitalization compared with receiving BNT162b2. This reduction translated to an absolute risk difference of 10 fewer medically attended COVID-19 events and 2.2 fewer hospitalizations per 10,000 vaccinated individuals.1,2

Researchers observed that this protective divergence accrued primarily after 90 days following vaccination, suggesting sustained durability over the principal fall and winter months. In addition, an exploratory analysis demonstrated a 39.3% relative reduction in hospitalizations for major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, or heart failure among veterans who received mRNA-1283.1

Unlike earlier mRNA vaccines encoding full-length spike proteins, mRNA-1283 specifically targets the receptor-binding domain and N-terminal domain, focusing immune responses on key neutralizing epitopes.1,3

An indirect treatment comparison using Bucher methodology anchored through mRNA-1273 corroborated these real-world findings, demonstrating a 22.8% relative effectiveness advantage for mRNA-1283 against symptomatic illness in adults 65 and older.3 Modeling projections further estimated that adopting mRNA-1283 over BNT162b2 could prevent an additional 46,176 hospitalizations and 6023 deaths nationally among high-risk adults during a single season.1

Seasonal Integration and Pharmacy Logistics for High-Risk Populations

These comparative effectiveness insights come at a pivotal moment as community pharmacists enter the 2026 and 2027 virus season under evolving national guidance.4

With federal policies shifting childhood COVID-19 vaccination to shared clinical decision-making and selecting the XFG lineage for updated formulations, clear recommendations from pharmacy teams remain critical for driving adult immunization rates.

Broader VA research published in Vaccine underlines the value of seasonal protection, showing that receiving updated COVID-19 shots alongside annual influenza vaccines reduced emergency department visits by 31.7% and hospitalizations by 43.6% over 180 days.2

Pharmacists evaluating seasonal inventory will also note key operational benefits, as mRNA-1283 features enhanced stability at standard refrigeration temperatures to simplify storage and routine distribution. By delivering confident recommendations for indicated vaccines including influenza, COVID-19, and RSV, pharmacists can ensure older adults and high-risk patients receive optimal protection throughout this respiratory virus season.3,4

“In this cohort study of US veterans during the 2025-2026 respiratory virus season, the mRNA-1283 vaccine was associated with a lower risk of medically attended COVID-19 compared with the BNT162b2 vaccine,” concluded authors of the current study.1 “Estimates consistently favored the mRNA-1283 vaccine across all evaluated medically attended COVID-19 outcomes. This evidence supports a potential benefit of the mRNA-1283 vaccine and may inform seasonal vaccine decision-making in an older, high-risk population.”

READ MORE: COVID-19 Resource Center

REFERENCES
1. McConeghy KW, Skov B, DeVone F, et al. Estimation of mRNA-1283 vs BNT162b2 COVID-19 vaccine effectiveness in older US veterans. JAMA Netw Open. 2026;9(11):e2644727. doi:10.1001/jamanetworkopen.2026.44727
2. Bergeson L. Two studies in US veterans find updated COVID vaccines protect against severe illness. University of Minnesota. November 18, 2026. Accessed November 19, 2026. https://www.cidrap.umn.edu/covid-19/two-studies-us-veterans-find-updated-covid-vaccines-protect-against-severe-illness
3. Beck E, Georgieva M, Wang WJ, et al. Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults. CMRO. 2025;41(4):721-732. doi:10.1080/03007995.2025.2466726
4. Gallagher A, Albert E, Goode K. 2026-2027 respiratory vaccine guidance for pharmacists. Drug Topics. September 2, 2026. Accessed November 19, 2026. https://www.drugtopics.com/view/2026-2027-respiratory-vaccine-guidance-for-pharmacists

Related to this article